Biotech firm AnaptysBio reports Q1 GAAP EPS of -$1.84, missing estimates, while revenue exceeds expectations by $6.69M.
AnaptysBio posted a Q1 GAAP loss per share of -$1.84, wider than expected by $1.04. The company’s collaboration revenue reached $25.56M, surpassing estimates by $6.69M despite an 8% year-over-year decline.
Cash reserves stood at $286.5 million as of March 31, 2026, down $25.1 million from $311.6 million at the end of 2025. The revenue beat contrasts with the earnings miss, highlighting mixed financial performance.
No immediate market reaction was disclosed in the release.